Metagenomi Therapeutics Statistics
Total Valuation
MGX has a market cap or net worth of $28.57 million. The enterprise value is -$36.89 million.
| Market Cap | 28.57M |
| Enterprise Value | -36.89M |
Important Dates
The next estimated earnings date is Tuesday, November 24, 2026, after market close.
| Earnings Date | Nov 24, 2026 |
| Ex-Dividend Date | n/a |
Share Statistics
MGX has 37.78 million shares outstanding. The number of shares has increased by 1.11% in one year.
| Current Share Class | 37.78M |
| Shares Outstanding | 37.78M |
| Shares Change (YoY) | +1.11% |
| Shares Change (QoQ) | +0.31% |
| Owned by Insiders (%) | 10.57% |
| Owned by Institutions (%) | 16.55% |
| Float | 25.54M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | n/a |
| PS Ratio | 4.03 |
| Forward PS | 3.80 |
| PB Ratio | 0.31 |
| P/TBV Ratio | 0.31 |
| P/FCF Ratio | n/a |
| P/OCF Ratio | n/a |
| PEG Ratio | n/a |
Enterprise Valuation
| EV / Earnings | n/a |
| EV / Sales | n/a |
| EV / EBITDA | n/a |
| EV / EBIT | n/a |
| EV / FCF | n/a |
Financial Position
The company has a current ratio of 3.43, with a Debt / Equity ratio of 0.39.
| Current Ratio | 3.43 |
| Quick Ratio | 3.14 |
| Debt / Equity | 0.39 |
| Debt / EBITDA | n/a |
| Debt / FCF | n/a |
| Interest Coverage | n/a |
Financial Efficiency
Return on equity (ROE) is -69.35% and return on invested capital (ROIC) is -35.75%.
| Return on Equity (ROE) | -69.35% |
| Return on Assets (ROA) | -30.82% |
| Return on Invested Capital (ROIC) | -35.75% |
| Return on Capital Employed (ROCE) | -79.93% |
| Weighted Average Cost of Capital (WACC) | 3.88% |
| Revenue Per Employee | $62,708 |
| Profits Per Employee | -$833,584 |
| Employee Count | 113 |
| Asset Turnover | 0.03 |
| Inventory Turnover | n/a |
Taxes
In the past 12 months, MGX has paid $44,000 in taxes.
| Income Tax | 44,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has decreased by -64.82% in the last 52 weeks. The beta is 0.83, so MGX's price volatility has been lower than the market average.
| Beta (5Y) | 0.83 |
| 52-Week Price Change | -64.82% |
| 50-Day Moving Average | 0.97 |
| 200-Day Moving Average | 1.26 |
| Relative Strength Index (RSI) | 39.31 |
| Average Volume (20 Days) | 167,911 |
Short Selling Information
The latest short interest is 1.29 million, so 3.42% of the outstanding shares have been sold short.
| Short Interest | 1.29M |
| Short Previous Month | 1.27M |
| Short % of Shares Out | 3.42% |
| Short % of Float | 5.06% |
| Short Ratio (days to cover) | 7.84 |
Income Statement
In the last 12 months, MGX had revenue of $7.09 million and -$94.20 million in losses. Loss per share was -$2.50.
| Revenue | 7.09M |
| Gross Profit | -87.35M |
| Operating Income | -99.95M |
| Pretax Income | -94.15M |
| Net Income | -94.20M |
| EBITDA | -94.86M |
| EBIT | -99.95M |
| Loss Per Share | -$2.50 |
Balance Sheet
The company has $101.67 million in cash and $36.21 million in debt, with a net cash position of $65.46 million or $1.73 per share.
| Cash & Cash Equivalents | 101.67M |
| Total Debt | 36.21M |
| Net Cash | 65.46M |
| Net Cash Per Share | $1.73 |
| Equity (Book Value) | 93.19M |
| Book Value Per Share | 2.46 |
| Working Capital | 78.52M |
Cash Flow
In the last 12 months, operating cash flow was -$83.32 million and capital expenditures -$214,000, giving a free cash flow of -$83.53 million.
| Operating Cash Flow | -83.32M |
| Capital Expenditures | -214,000 |
| Depreciation & Amortization | 5.09M |
| Net Borrowing | n/a |
| Free Cash Flow | -83.53M |
| FCF Per Share | -$2.21 |
Margins
| Gross Margin | n/a |
| Operating Margin | -1,410.57% |
| Pretax Margin | -1,328.69% |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
MGX does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| FCF Payout Ratio | n/a |
| Buyback Yield | -1.11% |
| Shareholder Yield | -1.11% |
| Earnings Yield | -331.04% |
| FCF Yield | -292.36% |
Analyst Forecast
The average price target for MGX is $7.00, which is 825.56% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $7.00 |
| Price Target Difference | 825.56% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 5 |
| Revenue Growth Forecast (3Y) | -43.85% |
| EPS Growth Forecast (3Y) | n/a |
Fair Value
There are several formulas that can be used to estimate the intrinsic value of a stock.
| Lynch Fair Value | n/a |
| Lynch Upside | n/a |
| Graham Number | n/a |
| Graham Upside | n/a |
| Graham Formula Value | n/a |
| Graham Formula Upside | n/a |
Stock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
| Altman Z-Score | n/a |
| Piotroski F-Score | 1 |